Systematic reviews of treatment for inflammatory demyelinating neuropathy

Journal of Anatomy

Volumn 200, Issue 4, 2002, Pages 331-339

  Hughes, R A C ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Inflammatory neuropathy; Paraprotein; Randomized controlled trial; Systematic review; Treatment

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; FLUDARABINE; GLYCOLIPID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYELIN; PARAPROTEIN; PREDNISOLONE; RITUXIMAB; STEROID;

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL PRACTICE; COCHRANE LIBRARY; CONTROLLED STUDY; DEMYELINATING NEUROPATHY; DRUG EFFICACY; GUILLAIN BARRE SYNDROME; HUMAN; MOTOR NEUROPATHY; NERVE FIBER MEMBRANE; PARAPROTEINEMIA; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PARAPROTEINEMIAS; PARAPROTEINS; POLYRADICULONEUROPATHY; RANDOMIZED CONTROLLED TRIALS;

EID: 0036252055     PISSN: 00218782     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-7580.2002.00041.x     Document Type: Review

References (75)

1. The inflammatory fesion in idiopathic polyneuritis. Its role in pathogenesis
2. Recurrent polyneuropathies and their corticosteroid treatment
3. IgG monoclonal paraproteinaemia and peripheral neuropathy
4. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome
5. Chronic inflammatory demyelinating polyradiculoneuropathy: Comparison of patients with and without an associated monoclonal gammopathy
6. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome
7. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome
8. A randomised controlled trial of IVIg in IgM paraproteinaemic demyelinating neuropathy
9. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy
10. Pure motor demyelinating neuropathy: Deterioration after steroid treatment and improvement with intravenous immunoglobulin
11. Chronic inflammatory polyradiculoneuropathy
12. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment
13. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy
14. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy
15. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance
16. Chronic inflammatory demyelinating polyradiculoneuropathy
17. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy
18. Rationale, potentials, and promise of systematic reviews
19. Report of a European Workshop on Multifocal Motor Neuropathy
20. An acute axonal form of Guillain-Barré polyneuropathy
21. Multifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebo-controlled study
22. Syndrome of ophthalmoplegia, ataxia and areflexia
23. Anti-PMP22 antibodies in patients with inflammatory neuropathy
24. The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange
25. Plasmapheresis and acute Guillain-Barré syndrome
26. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome
27. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy
28. Preceding infections, immune factors and outcome in Guillain-Barré syndrome
29. Acute motor axonal neuropathy: An antibody-mediated attack on axolemma
30. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy (CIDP): A double-blind, sham-controlled, cross-over study
31. Intravenous immunoglobulin treatment (IVIg) in chronic inflammatory demyelinating polyneuropathy (CIDP): A double-blind placebo-controlled cross-over study
32. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome
33. Pathogenesis of Guillain-Barré syndrome
34. Corticosteroid treatment for Guillain-Barré syndrome
35. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy
36. Intravenous immunoglobulin for Guillain-Barrě syndrome
37. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy
38. Effects of glucocorticoids on experimental allergic neuritis
39. Intravenous imunoglobulin in the treatment of multifocal motor neuropathy with persistent conduction blocks: A randomized double-blind placebo controlled study
40. Anti-MAG antibodies alter neurofilament spacing: A contribution to the pathogenesis of IgM anti-MAG paraproteinaemic neuropathy?
41. High-affinity anti-ganglioside IgG antibodies raised in complex ganglioside knockout mice: Reexamination of GD1a immunolocalization
42. Immunotherapy for IgM anti-Myelin-Associated Glycoprotein paraprotein-associated peripheral neuropathies
43. A randomised double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM
44. Plasmapheresis and Guillain-Barré Syndrome: Analysis of prognostic factors and the effect of plasmapheresis
45. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
46. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy
47. Multifocal motor neuropathy
48. A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain-Barré syndrome
49. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal
50. 'Chronic sensory demyelinating neuropathy': Chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy
51. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome
52. Miller Fisher anti-GQ1b antibodies: Alpha-latrotoxin-like effects on motor end plates
53. Chronic relapsing polyneuritis
54. Plasma Exchange for Guillain-Barré Syndrome
55. Sodium channel inactivation in an animal model of acute quadriplegic myopathy
56. Loss of electrical excitability in an animal model of acute quadriplegic myopathy
57. Multifocal acquired demyelinating motor and sensory motor neuropathy: The Lewis-Sumner syndrome
58. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Comparison of patients without and with monoclonal gammopathy
59. Chronic demyelinating neuropathy associated with benign IgM paraproteinaemia
60. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein
61. Recurrent and chronic relapsing Guillain-Barré polyneuritis
62. The Guillain-Barré syndrome: No longer a simple concept
63. Focal upper limb demyelinating neuropathy
64. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
65. Immunosuppressants for treating multifocal motor neuropathy
66. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: A double blind, placebo controlled study
67. Intravenous immunoglobulin (IVIG) in the treatment of chronic demyelinating polyradiculoneuropathy
68. Dutch Guillain-Barré Study Group A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome
69. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study
70. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy
71. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy
72. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: A double blind, placebo controlled study
73. Focal cranial nerve involvement in chronic inflammatory demyelinating polyneuropathy: Clinical and MRI evidence of peripheral and central lesions
74. PO protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy
75. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings